Literature DB >> 33625628

Main Role of Antibodies in Demyelination and Axonal Damage in Multiple Sclerosis.

Ursula Muñoz1, Cristina Sebal2, Esther Escudero2, Margaret Esiri3, John Tzartos4, Carolyn Sloan3, Mari Cruz Sadaba5.   

Abstract

Antibodies and oxidative stress are hallmarks of multiple sclerosis (MS) lesions. We aimed to clarify the relation between them, their role in MS patients and to investigate their specificity, comparing MS with classical neurodegenerative diseases (ND). Brain samples from 14 MS cases, 6 with ND and 9 controls (without neurological diseases). Immunohistochemistry assays were used to detect oxidized lipids (EO6), IgG and IgM, oligodendrocytes (Olig2), axons (NF, neurofilament) and cellular (TUNEL) and axonal damage (APP, amyloid precursor protein). We did not observe EO6 in controls. All samples from MS patients showed EO6 in oligodendrocytes and axons within lesions. We did not detect co-localization between EO6 and antibodies. Neither did we between EO6 and TUNEL or APP. 94.4% of TUNEL-positive cells in normal appearing white matter were also stained for IgG and 75.5% for IgM. IgM, but not IgG, co-localized with APP. EO6 was associated with axonal damage in amyotrophic lateral sclerosis (ALS). We did not observe association between antibodies and cellular or axonal damage in ND patients. MS patients showed a higher number of B cells and plasma cells in the lesions and meninges than controls. The number of B cells and plasma cells was associated with the presence of antibodies and with the activity of the lesions. We observed a main role of B lymphocytes in the development of MS lesions. Antibodies contribute to the oligodendrocyte and axonal damage in MS. Oxidative stress was associated with axonal damage in ALS.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.

Entities:  

Keywords:  Antibodies; Autoimmunity; Multiple sclerosis; Neurodegenerative diseases; Oxidative stress

Mesh:

Substances:

Year:  2021        PMID: 33625628     DOI: 10.1007/s10571-021-01059-6

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  47 in total

Review 1.  Innate and acquired immunity in atherogenesis.

Authors:  Christoph J Binder; Mi-Kyung Chang; Peter X Shaw; Yury I Miller; Karsten Hartvigsen; Asheesh Dewan; Joseph L Witztum
Journal:  Nat Med       Date:  2002-11       Impact factor: 53.440

2.  Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients.

Authors:  Ranjan Dutta; Jennifer McDonough; Xinghua Yin; John Peterson; Ansi Chang; Thalia Torres; Tatyana Gudz; Wendy B Macklin; David A Lewis; Robert J Fox; Richard Rudick; Karoly Mirnics; Bruce D Trapp
Journal:  Ann Neurol       Date:  2006-03       Impact factor: 10.422

3.  Elevated protein carbonylation in the brain white matter and gray matter of patients with multiple sclerosis.

Authors:  Oscar A Bizzozero; Gisela DeJesus; Kelly Callahan; Andrzej Pastuszyn
Journal:  J Neurosci Res       Date:  2005-09-01       Impact factor: 4.164

4.  Antibodies to calcium channels from ALS patients passively transferred to mice selectively increase intracellular calcium and induce ultrastructural changes in motoneurons.

Authors:  J I Engelhardt; L Siklós; L Kömüves; R G Smith; S H Appel
Journal:  Synapse       Date:  1995-07       Impact factor: 2.562

5.  IgG reactivity in the spinal cord and motor cortex in amyotrophic lateral sclerosis.

Authors:  J I Engelhardt; S H Appel
Journal:  Arch Neurol       Date:  1990-11

6.  B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions.

Authors:  S E Baranzini; M C Jeong; C Butunoi; R S Murray; C C Bernard; J R Oksenberg
Journal:  J Immunol       Date:  1999-11-01       Impact factor: 5.422

7.  Experimental destruction of substantia nigra initiated by Parkinson disease immunoglobulins.

Authors:  S Chen; W D Le; W J Xie; M E Alexianu; J I Engelhardt; L Siklós; S H Appel
Journal:  Arch Neurol       Date:  1998-08

8.  Peroxynitrite formation within the central nervous system in active multiple sclerosis.

Authors:  A H Cross; P T Manning; R M Keeling; R E Schmidt; T P Misko
Journal:  J Neuroimmunol       Date:  1998-08-01       Impact factor: 3.478

9.  Homogeneity of active demyelinating lesions in established multiple sclerosis.

Authors:  Esther C W Breij; Bianca P Brink; Rob Veerhuis; Christa van den Berg; Rianka Vloet; Riqiang Yan; Christine D Dijkstra; Paul van der Valk; Lars Bö
Journal:  Ann Neurol       Date:  2008-01       Impact factor: 10.422

Review 10.  Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report.

Authors:  M Andersson; J Alvarez-Cermeño; G Bernardi; I Cogato; P Fredman; J Frederiksen; S Fredrikson; P Gallo; L M Grimaldi; M Grønning
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-08       Impact factor: 10.154

View more
  3 in total

1.  Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study.

Authors:  Nicola Capasso; Raffaele Palladino; Vincenza Cerbone; Antonio Luca Spiezia; Bianca Covelli; Antonia Fiore; Roberta Lanzillo; Antonio Carotenuto; Maria Petracca; Lucia Stanziola; Giulia Scalia; Vincenzo Brescia Morra; Marcello Moccia
Journal:  J Neurol       Date:  2022-09-01       Impact factor: 6.682

Review 2.  B cells in central nervous system disease: diversity, locations and pathophysiology.

Authors:  Rajiv W Jain; V Wee Yong
Journal:  Nat Rev Immunol       Date:  2021-12-13       Impact factor: 108.555

3.  Serum levels of IgM to phosphatidylcholine predict the response of multiple sclerosis patients to natalizumab or IFN-β.

Authors:  Úrsula Muñoz; Cristina Sebal; Esther Escudero; Elena Urcelay; Rafael Arroyo; Maria A García-Martínez; Francisco J Quintana; Roberto Álvarez-Lafuente; Maria Cruz Sádaba
Journal:  Sci Rep       Date:  2022-08-03       Impact factor: 4.996

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.